The EUROPEAN UNION drug watchdog has said it is evaluating the possible use of Moderna’s Covid vaccine for children aged five and under.
The under-fives are the only group that is not yet eligible for the jab in most countries.
“We have just started the evaluation of a Moderna application to extend the use of Spikevax to children aged six months to five years,” said Marco Cavaleri, head of anti-infectives and vaccines at the European Medicines Agency (EMA).
“This is the first application for this young age group,” Cavaleri said.
In February, the EMA’s human medicines committee had already recommended extending the indication for the Spikevax vaccine to include use in children aged 6 to 11 years.
The jab, developed by US-based Moderna, had already been approved for adults and children 12 and older.
No news is bad news
Support the journal
Their contributions will help us continue to deliver the stories that matter to you
support us now
The Amsterdam-based EMA has so far approved five vaccines for use in the EU: Pfizer and Moderna, which use messenger RNA technology, AstraZeneca and Johnson & Johnson, which use viral vector technology, and Novavax, which is based on a spike protein produced in a laboratory